On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

Regeneron Pharmaceuticals, Inc. reported second-quarter earnings that significantly exceeded analyst expectations, with adjusted earnings per share reaching $12.89 compared to the $8.43 consensus ...

US Biotech Regeneron Pharmaceuticals today announced financial results for the second quarter of 2025 and provided a business ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

The S&P 500 Index ($SPX) (SPY) today is down -1.70%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.48%, and the ...